Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.

Farlow M, Anand R, Messina J Jr, Hartman R, Veach J.

Eur Neurol. 2000;44(4):236-41.

PMID:
11096224
2.

Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.

Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R.

Arch Neurol. 2001 Mar;58(3):417-22.

PMID:
11255445
3.

An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors.

Kumar V, Anand R, Messina J, Hartman R, Veach J.

Eur J Neurol. 2000 Mar;7(2):159-69.

PMID:
10809936
4.

Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.

Farlow M, Potkin S, Koumaras B, Veach J, Mirski D.

Arch Neurol. 2003 Jun;60(6):843-8.

PMID:
12810489
6.

Rivastigmine for Alzheimer's disease.

Birks JS, Grimley Evans J.

Cochrane Database Syst Rev. 2015 Apr 10;(4):CD001191. doi: 10.1002/14651858.CD001191.pub3. Review.

PMID:
25858345
7.

Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.

Burns A, Spiegel R, Quarg P.

Int J Geriatr Psychiatry. 2004 Mar;19(3):243-9.

PMID:
15027039
8.

Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.

Marin D, Amaya K, Casciano R, Puder KL, Casciano J, Chang S, Snyder EH, Cheng I, Cuccia AJ.

Int Psychogeriatr. 2003 Dec;15(4):385-98.

PMID:
15000418
9.

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stähelin HB, Hartman R, Gharabawi M.

BMJ. 1999 Mar 6;318(7184):633-8. Erratum in: BMJ 2001 Jun 16;322(7300):1456.

10.

Rivastigmine for Alzheimer's disease.

[No authors listed]

Drug Ther Bull. 2000 Feb;38(2):15-6. Review.

PMID:
10829350
11.

Rivastigmine for Alzheimer's disease.

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M.

Cochrane Database Syst Rev. 2000;(4):CD001191. Review. Update in: Cochrane Database Syst Rev. 2009;(2):CD001191.

PMID:
11034705
12.

Rivastigmine for Alzheimer's disease.

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191. doi: 10.1002/14651858.CD001191.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;4:CD001191.

PMID:
19370562
13.

Cholinesterase inhibitors for Alzheimer's disease.

Birks J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Review.

PMID:
16437532
14.

Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.

Alva G, Isaacson R, Sadowsky C, Grossberg G, Meng X, Somogyi M.

Int J Geriatr Psychiatry. 2014 Sep;29(9):920-7. doi: 10.1002/gps.4080. Epub 2014 Feb 18.

PMID:
24549933
15.

Rivastigmine. A review of its use in Alzheimer's disease.

Spencer CM, Noble S.

Drugs Aging. 1998 Nov;13(5):391-411. Review.

PMID:
9829166
16.

Rivastigmine for Alzheimer's disease.

Birks J, Iakovidou V, Tsolaki M.

Cochrane Database Syst Rev. 2000;(2):CD001191. Review. Update in: Cochrane Database Syst Rev. 2000;(4):CD001191.

PMID:
10796621
17.

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.

Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R.

Int J Geriatr Psychiatry. 2007 May;22(5):456-67.

PMID:
17380489
18.

Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.

Farlow MR, Grossberg GT, Meng X, Olin J, Somogyi M.

Int J Geriatr Psychiatry. 2011 Dec;26(12):1236-43. doi: 10.1002/gps.2669. Epub 2010 Dec 23.

PMID:
22068922
19.

A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.

Karaman Y, Erdoğan F, Köseoğlu E, Turan T, Ersoy AO.

Dement Geriatr Cogn Disord. 2005;19(1):51-6. Epub 2004 Sep 21.

20.

Supplemental Content

Support Center